89Bio Inc at Bank of America Global Healthcare Conference Transcript
So we have -- I'm Geoff Meacham, the Biopharma Analyst here at B of A. We're thrilled to have 89bio. Rohan is up on the stage with me. So thank you for coming.
Yeah. Thanks for having us.
Questions & Answers
Of course, yeah. So maybe just give us a status update on NASH following recent data, and what we could expect more from --? I'm assuming that [Easel] will coming up.
Sure. So I just mentioned we had our NASH Phase 2b results read out in the end of March. And we are incredibly excited about the data we've put out with pegozafermin.
So for background who don't know, our company is late-stage clinical company focused liver and cardio-metabolic diseases. And our lead program is pegozafermin. And this is the FGF21 analog, which we believe has the potential to be transformational in these indications.
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |